HELRIK AND LOUW AND PARTNERS COMPANY LTD

Their core work

Helrik and Louw and Partners is a London-based private company that participates in EU-funded research consortia as an industry partner, contributing real-world business context and commercial expertise to academic-led projects. Their involvement is concentrated in health and life sciences — specifically health tourism, aging, environmental wellness, and cancer treatment outcomes. In MSCA-RISE projects, industry partners like this company typically host or exchange researchers, provide access to industry networks, and help translate research findings toward commercial application. The precise nature of their core business activity is not evident from project data alone, but their thematic portfolio points toward health services, wellness consulting, or life sciences commercialisation.

What they specialise in

How they've shifted over time

In their early projects (2017), the company's focus was on environmental and lifestyle factors affecting health — green spaces, tourism settings, micro-environments, and aging well-being. By 2018, the focus moved sharply toward clinical territory: postoperative care, immunotherapy, and cancer survivorship. This shift suggests either a broadening of the company's commercial interests from wellness to healthcare, or that they were brought into the CANCER consortium specifically for their life sciences industry connections rather than any thematic continuity.

The jump from wellness tourism to oncology immunotherapy in a single year is a significant thematic leap — future collaborators should verify whether this reflects a genuine strategic pivot in the company's business or opportunistic participation in unrelated consortia.

How they like to work

Helrik and Louw and Partners has never led an H2020 project — both participations are as consortium members, typical of an industry partner in MSCA-RISE schemes where the primary role is hosting researchers or enabling knowledge transfer rather than driving scientific direction. Their two projects collectively involved 29 unique partners across 7 countries, indicating involvement in large, multi-institution consortia rather than tight bilateral collaborations. This profile suits an organisation comfortable operating in the background of academic-led initiatives rather than fronting research programmes.

With 29 unique consortium partners across 7 countries in just two projects, the company has been exposed to a reasonably broad European network, though the depth of those relationships is unclear given the MSCA-RISE staff-exchange format. Their international footprint is European in scope.

What sets them apart

This company occupies a narrow but specific niche: a UK-based private sector partner willing to engage with academic MSCA-RISE consortia across both health tourism/wellness and oncology. Post-Brexit, UK participation in Horizon Europe is more complex, which may affect their future collaboration availability. Their dual exposure to lifestyle health and clinical cancer research could make them useful as an industry bridge between wellness and medical sectors, but the limited project record makes it difficult to assess how deep their expertise runs in either area.

Highlights from their portfolio

• CANCER
  The larger of the two grants (EUR 162,000) and the longer project (2018–2023), addressing a high-impact clinical challenge — personalised postoperative immunotherapy — in what appears to be a significant thematic departure from the company's earlier health tourism work.
• CHARMED
  Represents the company's earliest H2020 engagement, focused on an unusual intersection of environmental science, tourism, and aging health — a commercially interesting combination for health resort or wellness industry players.